Investments

2A Biosciences develops novel therapeutics targeting serotonin 2A receptors. Building on pioneering research by Drs. Charles and David Nichols, the company harnesses the anti-inflammatory and neuroplastic benefits of serotonin 2A agonists without inducing hallucinogenic effects. Their innovative approach unlocks the therapeutic potential of these molecules for treating inflammatory conditions and supporting tissue repair.

Amandala Neuro is an early-stage biotech company developing patient-centered psychedelic-assisted therapies designed to fit within existing psychiatric care models for treating mental health conditions.

Anthropic, founded by former members of OpenAI, specializes in developing general AI systems and language models, with a company ethos of responsible AI usage.

Beam is improving urban mobility with shared e-scooters, e-bikes and e-mopeds, bringing a safe and sustainable transportation to cities in Asia Pacific.

Bexson Biomedical is a biopharmaceutical company focused on delivering small molecules subcutaneously to enable home health delivery. They are initially focused on addressing the opioid crisis by developing non-opiod therapy for acute pain management.

Calm offers a global health and wellness brand application designed to help its users meditate and relax. Their mission is to make the world happier and healthier by developing a range of digital and physical products that enhance mental fitness and alleviate anxiety, depression, insomnia, and stress.

Carbon Crusher offers carbon crushing as a service to the public or private road owners or contractors, thus having positive impact on climate, infrastructure investments and road safety.

Charm Industrial is working to return the atmosphere to 280 ppm CO₂. We design, build and operate a fleet of mobile fast pyrolyzers that convert ag and forest biomass residues into bio-oil for use in carbon removal and direct-reduced-iron steelmaking.

Through providing independent psychedelic-specialist CRO services, Clerkenwell will accelerate the adoption of these treatments across Europe. The team is passionate about putting patients at the center of clinical trial design and delivering gold standard therapy protocols.

Cognigenics is revolutionizing the way mental health conditions are treated. They utilize genetic neuroengineering technology to precisely and noninvasively target and modulate the underlying neural circuits responsible for mental health disorders, such as anxiety, depression, and cognitive impairment.

Combining cutting-edge neuroscience and neurobiology with the long-standing traditions of plant medicine, Dimensions focuses on restorative well-being and transformational growth in safe, luxurious environments.

Entheos Labs is bioengineering novel psychedelic botanicals to deliver a new generation of psychedelic-derived therapeutic molecules.